Approaches to classical HL treatment
| Treatment . | Cumulative doses . | Expected toxicity . | Radiation . | Reference . |
|---|---|---|---|---|
| OEPA ×2 | Vincristine 9 mg/m2 Etoposide 1250 mg/m2 Prednisone 1800 mg/m2 Doxorubicin 160 mg/m2 | Peripheral neuropathy AVN Cardiomyopathy | 126/188 (67%) 19.8 Gy IFRT | Mauz-Korholz et al6 |
| ABVD ×4 | Doxorubicin 200 mg/m2 Bleomycin 80 U/m2 Vinblastine 48 mg/m2 Dacarbazine 3000 mg/m2 | Myelosuppression Peripheral neuropathy Pneumonitis Cardiomyopathy | none | COG AHOD18227 |
| Bv-AVD ×4 | Brentuximab vedotin 9.6 mg/kg Doxorubicin 200 mg/m2 Vinblastine 48 mg/m2 Dacarbazine 3000 mg/m2 | Myelosuppression Peripheral neuropathy Cardiomyopathy | none | Abramson et al8 |
| Bv-AVD ×6 | Brentuximab vedotin 14 mg/kg Doxorubicin 300 mg/m2 Vinblastine 72 mg/m2 Dacarbazine 4500 mg/m2 | Myelosuppression Peripheral neuropathy Cardiomyopathy | 2/664 (0.003%) Investigator discretion | Connors et al9 |
| Treatment . | Cumulative doses . | Expected toxicity . | Radiation . | Reference . |
|---|---|---|---|---|
| OEPA ×2 | Vincristine 9 mg/m2 Etoposide 1250 mg/m2 Prednisone 1800 mg/m2 Doxorubicin 160 mg/m2 | Peripheral neuropathy AVN Cardiomyopathy | 126/188 (67%) 19.8 Gy IFRT | Mauz-Korholz et al6 |
| ABVD ×4 | Doxorubicin 200 mg/m2 Bleomycin 80 U/m2 Vinblastine 48 mg/m2 Dacarbazine 3000 mg/m2 | Myelosuppression Peripheral neuropathy Pneumonitis Cardiomyopathy | none | COG AHOD18227 |
| Bv-AVD ×4 | Brentuximab vedotin 9.6 mg/kg Doxorubicin 200 mg/m2 Vinblastine 48 mg/m2 Dacarbazine 3000 mg/m2 | Myelosuppression Peripheral neuropathy Cardiomyopathy | none | Abramson et al8 |
| Bv-AVD ×6 | Brentuximab vedotin 14 mg/kg Doxorubicin 300 mg/m2 Vinblastine 72 mg/m2 Dacarbazine 4500 mg/m2 | Myelosuppression Peripheral neuropathy Cardiomyopathy | 2/664 (0.003%) Investigator discretion | Connors et al9 |
Italicized agents were avoided. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; Bv-AVD, brentuximab vedotin, doxorubicin; COG, Children’s Oncology Group; IFRT, involved field radiation therapy; vinblastine, and dacarbazine; OEPA, vincristine, etoposide, prednisone, doxorubicin.